CAVALLONI, CHIARA
CAVALLONI, CHIARA
DIPARTIMENTO DI MEDICINA MOLECOLARE
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
2017-01-01 Rumi, E; Boveri, E; Bellini, M; Pietra, D; Ferretti, Vv; Sant'Antonio, E; Cavalloni, C; Casetti, Ic; Roncoroni, E; Ciboddo, M; Benvenuti, P; Landini, B; Fugazza, E; Troletti, D; Astori, C; Cazzola, M
Diagnosis and management of prefibrotic myelofibrosis.
2018-01-01 Rumi, E; Sant'Antonio, E; Boveri, E; Pietra, D; Cavalloni, C; Roncoroni, E; Astori, C; Arcaini, L
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
2016-01-01 Pietra, D.; Rumi, E.; Ferretti, V. V.; Di Buduo, C. A.; Milanesi, C.; Cavalloni, C.; Sant'Antonio, E.; Abbonante, V.; Moccia, F.; Casetti, I. C.; Bellini, M.; Renna, M. C.; Roncoroni, E.; Fugazza, E.; Astori, C.; Boveri, E.; Rosti, V.; Barosi, G.; Balduini, A.; Cazzola, M.
Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological study
2023-01-01 Michelerio, Andrea; Tomasini, Carlo; Fiandrino, Giacomo; De Amici, Mara; Varettoni, Marzia; Defrancesco, Irene; Cavalloni, Chiara; Brazzelli, Valeria; Derlino, Federica; Paulli, Marco; Arcaini, Luca; Vassallo, Camilla
Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological study
2023-01-01 Michelerio, Andrea; Tomasini, Carlo; Fiandrino, Giacomo; De Amici, Mara; Varettoni, Marzia; Defrancesco, Irene; Cavalloni, Chiara; Brazzelli, Valeria; Derlino, Federica; Paulli, Marco; Arcaini, Luca; Vassallo, Camilla
Facing erythrocytosis: Results of an international physician survey.
2019-01-01 Rumi, E; Mcmullin, Mf; Harrison, C; Ellis, Mh; Barzilai, M; Sarid, N; Mesa, R; Paoli, C; Angona, A; Sant'Antonio, E; Ferretti, Vv; Cavalloni, C; Casetti, Ic; Trotti, C; Barbui, T.
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group.
2020-01-01 Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Barraco, D; Rambaldi, A; Caramella, M; Komrokji, Rs; Kiladjian, Jj; Gotlib, J; Iurlo, A; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Albano, F; Benevolo, G; Cavalloni, C; Uccella, S; Accetta, R; Siracusa, C; Agnoli, S; Merli, M; Barbui, T; Bertù, L; Cazzola, M; Vannucchi, Am; Passamonti, F.
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib
2020-01-01 Rumi, E.; Sant'Antonio, E.; Cavalloni, C.; Comolli, G.; Ferretti, V. V.; Cassaniti, I.; Pietra, D.; Trotti, C.; Ciboddo, M.; Furione, M.; Vanni, D.; Casetti, I. C.; Favaron, C.; Baldanti, F.; Arcaini, L.; Cazzola, M.
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin
2014-01-01 Pietra, Daniela; Rumi, Elisa; Chiara, Milanesi; DI BUDUO, CHRISTIAN ANDREA; Bellini, Marta; Casetti, ILARIA CAROLA; Cavalloni, Chiara; Sant'Antonio, Emanuela; Abbonante, Vittorio; Renna, MARIA CONCETTA; Ferretti, VIRGINIA VALERIA; Boveri, Emanuela; Balduini, Alessandra; Pascutto, Cristiana; Cazzola, Mario
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
2018-01-01 Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Pietra, D; Barbui, T; Rotunno, G; Vannucchi, Am; Passamonti, F
Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera.
2018-01-01 Bertozzi, I; Rumi, E; Cavalloni, C; Cazzola, M; Fabris, F; Randi, Ml
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms
2019-01-01 Rumi, E; Zibellini, S; Boveri, E; Cavalloni, C; Riboni, R; Casetti, Ic; Ciboddo, M; Trotti, C; Favaron, C; Pietra, D; Candido, C; Ferretti, Vv; Cazzola, M; Arcaini, L.
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
2019-01-01 Mora, B; Rumi, E; Guglielmelli, P; Barraco, D; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Pietra, D; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Giorgino, T; Passamonti, F.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
2019-01-01 Maffioli, M; Giorgino, T; Mora, B; Iurlo, A; Elli, E; Finazzi, Mc; Caramella, M; Rumi, E; Carraro, Mc; Polverelli, N; D'Adda, M; Malato, S; Rossi, M; Molteni, A; Vismara, A; Sissa, C; Spina, F; Anghilieri, M; Cattaneo, D; Renso, R; Bellini, M; Pioltelli, Ml; Cavalloni, C; Barraco, D; Accetta, R; Bertù, L; Della Porta, Mg; Passamonti, F.
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
2020-01-01 Guglielmelli, P; Carobbio, A; Rumi, E; De Stefano, V; Mannelli, L; Mannelli, F; Rotunno, G; Coltro, G; Betti, S; Cavalloni, C; Finazzi, Mc; Thiele, J; Cazzola, M; Vannucchi, Am; Barbui, T.
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
2018-01-01 Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Merli, M; Pietra, D; Casalone, R; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Passamonti, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. | 1-gen-2017 | Rumi, E; Boveri, E; Bellini, M; Pietra, D; Ferretti, Vv; Sant'Antonio, E; Cavalloni, C; Casetti, Ic; Roncoroni, E; Ciboddo, M; Benvenuti, P; Landini, B; Fugazza, E; Troletti, D; Astori, C; Cazzola, M | |
| Diagnosis and management of prefibrotic myelofibrosis. | 1-gen-2018 | Rumi, E; Sant'Antonio, E; Boveri, E; Pietra, D; Cavalloni, C; Roncoroni, E; Astori, C; Arcaini, L | |
| Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms | 1-gen-2016 | Pietra, D.; Rumi, E.; Ferretti, V. V.; Di Buduo, C. A.; Milanesi, C.; Cavalloni, C.; Sant'Antonio, E.; Abbonante, V.; Moccia, F.; Casetti, I. C.; Bellini, M.; Renna, M. C.; Roncoroni, E.; Fugazza, E.; Astori, C.; Boveri, E.; Rosti, V.; Barosi, G.; Balduini, A.; Cazzola, M. | |
| Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological study | 1-gen-2023 | Michelerio, Andrea; Tomasini, Carlo; Fiandrino, Giacomo; De Amici, Mara; Varettoni, Marzia; Defrancesco, Irene; Cavalloni, Chiara; Brazzelli, Valeria; Derlino, Federica; Paulli, Marco; Arcaini, Luca; Vassallo, Camilla | |
| Eosinophilic dermatosis of hematologic malignancy in patients with chronic lymphocytic leukemia/non-Hodgkin's B lymphoma: a single center prospective clinico-pathological study | 1-gen-2023 | Michelerio, Andrea; Tomasini, Carlo; Fiandrino, Giacomo; De Amici, Mara; Varettoni, Marzia; Defrancesco, Irene; Cavalloni, Chiara; Brazzelli, Valeria; Derlino, Federica; Paulli, Marco; Arcaini, Luca; Vassallo, Camilla | |
| Facing erythrocytosis: Results of an international physician survey. | 1-gen-2019 | Rumi, E; Mcmullin, Mf; Harrison, C; Ellis, Mh; Barzilai, M; Sarid, N; Mesa, R; Paoli, C; Angona, A; Sant'Antonio, E; Ferretti, Vv; Cavalloni, C; Casetti, Ic; Trotti, C; Barbui, T. | |
| Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. | 1-gen-2020 | Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Barraco, D; Rambaldi, A; Caramella, M; Komrokji, Rs; Kiladjian, Jj; Gotlib, J; Iurlo, A; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Albano, F; Benevolo, G; Cavalloni, C; Uccella, S; Accetta, R; Siracusa, C; Agnoli, S; Merli, M; Barbui, T; Bertù, L; Cazzola, M; Vannucchi, Am; Passamonti, F. | |
| Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib | 1-gen-2020 | Rumi, E.; Sant'Antonio, E.; Cavalloni, C.; Comolli, G.; Ferretti, V. V.; Cassaniti, I.; Pietra, D.; Trotti, C.; Ciboddo, M.; Furione, M.; Vanni, D.; Casetti, I. C.; Favaron, C.; Baldanti, F.; Arcaini, L.; Cazzola, M. | |
| Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin | 1-gen-2014 | Pietra, Daniela; Rumi, Elisa; Chiara, Milanesi; DI BUDUO, CHRISTIAN ANDREA; Bellini, Marta; Casetti, ILARIA CAROLA; Cavalloni, Chiara; Sant'Antonio, Emanuela; Abbonante, Vittorio; Renna, MARIA CONCETTA; Ferretti, VIRGINIA VALERIA; Boveri, Emanuela; Balduini, Alessandra; Pascutto, Cristiana; Cazzola, Mario | |
| Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. | 1-gen-2018 | Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Pietra, D; Barbui, T; Rotunno, G; Vannucchi, Am; Passamonti, F | |
| Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera. | 1-gen-2018 | Bertozzi, I; Rumi, E; Cavalloni, C; Cazzola, M; Fabris, F; Randi, Ml | |
| Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms | 1-gen-2019 | Rumi, E; Zibellini, S; Boveri, E; Cavalloni, C; Riboni, R; Casetti, Ic; Ciboddo, M; Trotti, C; Favaron, C; Pietra, D; Candido, C; Ferretti, Vv; Cazzola, M; Arcaini, L. | |
| Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. | 1-gen-2019 | Mora, B; Rumi, E; Guglielmelli, P; Barraco, D; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Pietra, D; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Giorgino, T; Passamonti, F. | |
| Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. | 1-gen-2019 | Maffioli, M; Giorgino, T; Mora, B; Iurlo, A; Elli, E; Finazzi, Mc; Caramella, M; Rumi, E; Carraro, Mc; Polverelli, N; D'Adda, M; Malato, S; Rossi, M; Molteni, A; Vismara, A; Sissa, C; Spina, F; Anghilieri, M; Cattaneo, D; Renso, R; Bellini, M; Pioltelli, Ml; Cavalloni, C; Barraco, D; Accetta, R; Bertù, L; Della Porta, Mg; Passamonti, F. | |
| Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. | 1-gen-2020 | Guglielmelli, P; Carobbio, A; Rumi, E; De Stefano, V; Mannelli, L; Mannelli, F; Rotunno, G; Coltro, G; Betti, S; Cavalloni, C; Finazzi, Mc; Thiele, J; Cazzola, M; Vannucchi, Am; Barbui, T. | |
| Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. | 1-gen-2018 | Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Merli, M; Pietra, D; Casalone, R; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Passamonti, F. |